# Post-marketing safety analyses for multiple marketed products in collaboration with the D:A:D study (206247)

**First published:** 21/04/2017

**Last updated:** 27/05/2024

Study Finalised

## Administrative details

**EU PAS number**

EUPAS18709

**Study ID**

42149

**DARWIN EU® study**

No

**Study countries**

- Argentina
- Australia
- Austria
- Belarus

- Belgium
- Croatia
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Israel
- Italy
- Latvia
- Lithuania
- Luxembourg
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Serbia
- Slovakia
- Spain
- Sweden
- Switzerland
- Ukraine
- United Kingdom
- United States

**Study status**

Finalised

# Research institutions and networks

## Institutions

### ViiV Healthcare

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

# Contact details

**Study institution contact**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

Pharma.CDR@gsk.com

**Primary lead investigator**

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

# Study timelines

**Date when funding contract was signed**
Planned: 07/04/2017

Actual: 05/04/2017

---

**Study start date**
Planned: 28/04/2017

Actual: 27/04/2017

---

**Data analysis start date**
Planned: 28/04/2017

Actual: 27/04/2017

---

**Date of final study report**
Planned: 15/08/2017

Actual: 26/10/2017

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

ViiV Healthcare

## Study protocol

viiv-206247-protocol-redact.pdf (128.97 KB)

## Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

# Methodological aspects

## Study type

## Study type list

**Study topic:**

Disease /health condition

Human medicinal product

**Study type:**

Non-interventional study

**Scope of the study:**

Other

Safety study (incl. comparative)

**If ‘other’, further details on the scope of the study**

Retrospective analysis of prospectively collected data

**Data collection methods:**

Secondary use of data

**Main study objective:**

To describe any safety issues that arise among hepatically-impaired individuals exposed to abacavir (ABC) containing products or fosamprenavir, to determine the risk of carcinogenicity following exposure to ABC containing products and lamivudine/zidovudine, and to determine the risk of hepatotoxicity and ischaemic cardiac events following exposure to maraviroc and fosamprenavir.

## Study Design

**Non-interventional study design**

Cohort

Other

---

**Non-interventional study design, other**

Retrospective analysis of prospectively collected data from the D:A:D study

## Study drug and medical condition

**Study drug International non-proprietary name (INN) or common name**

ABACAVIR

FOSAMPRENAVIR

LAMIVUDINE

MARAVIROC

ZIDOVUDINE

---

**Medical condition to be studied**

HIV infection

## Population studied

**Short description of the study population**

All D:A:D participants who have evidence of co-infection with hepatitis B virus (HBV)/ hepatitis C virus (HCV) and/or chronic liver enzyme elevations (CLEEs) at the time of initiating one of the three treatments/combinations will be included. D:A:D collects data on alanine transaminase (ALT), AST, total bilirubin, platelet counts, albumin, creatinine, and haemoglobin and a host of other laboratory testing. Participants from cohorts that do not provide information on ALT levels will be excluded and CLEEs will be defined as in the recent D:A:D paper by Kovari et al. (1). The study population will therefore be split into three groups at the time of initiation of each treatment/combination: (i) those with HCV and/or HBV infection and no CLEE; (ii) those with no HCV and/or HBV but with CLEE; and (iii) those with HCV and/or HBV and CLEE. Due to the estimated small number of study participants with chronic hepatic impairment and/or CLEE, and the possibility that the antiretroviral drugs may themselves induce hepatic impairment or liver enzyme elevation, the groups will be defined at the time of first exposure to the treatment/combination and will not be updated if an individual's status changes (e.g. if his/her ALT levels fall or if the individual subsequently becomes co-infected with HCV/HBV). Participants whose first ALT level in the dataset post-dates the start of the treatment/combination will be excluded. Where possible, dosing levels will be captured for the hepatically-impaired individuals for the relevant products.

Aim 2: All D:A:D participants without a prior cancer at D:A:D study enrolment who are enrolled from cohorts that provide data on cancer incidence will be included. Individuals who have died or are lost-to-follow-up before the cohort-specific baseline date for cancer analyses (2004 onwards) will be excluded.

Aims 3 and 4: All D:A:D participants without liver impairment (hepatotoxicity includes end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), and CLEE) or without a prior myocardial infarction (MI) at D:A:D study entry. Analyses of liver impairment will additionally exclude those from cohorts that

do not provide data on ALT levels.

**Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

**Special population of interest**

Immunocompromised

**Estimated number of subjects**

0

## Study design details

**Outcomes**

Safety events, cancer events, hepatotoxicity and ischaemic cardiac events

**Data analysis plan**

Descriptive statistics will be used to summarize event rates as the numbers are expected to be small. If the number of events is sufficient, Poisson regression can be performed to calculate relative rates for different exposure categories.

## Documents

**Study results**

viiv-206247-clinical-study-report-redact.pdf (8.05 MB)

# Data management

## ENGaGR Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

# Data sources

**Data sources (types)**

Other

**Data sources (types), other**

D:A:D Study

# Use of a Common Data Model (CDM)

**CDM mapping**

No

# Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

# Data characterisation

**Data characterisation conducted**

No